# 119-hr-8339: Drug Origin Transparency Act of 2026

119-hr-8339, Drug Origin Transparency Act of 2026, is a 119th Congress bill sponsored by Rep. Matsui, Doris O. [D-CA-7] (D-CA); status introduced; PRIA reads it as touching household money (as of 2026-11-01).

- Canonical: https://policyrisk.com/legislation/119-hr-8339
- As of: 2026-11-01
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Bill: 119-hr-8339
- Congress: 119
- Title: Drug Origin Transparency Act of 2026
- Status: introduced
- Introduced: 2026-04-16
- Sponsor: Rep. Matsui, Doris O. [D-CA-7] (D-CA)
- Cosponsors: 3
- Policy area: Health
- Touches household money: yes
- Last recorded action: 2026-11-01

## Summary

**Require full disclosure of a drug's origins and suppliers.** This bill would require manufacturers to report supplier identities and the amounts of drug made using each supplier's materials, file reports more than once a year but no more than 4 times a year, and put original API manufacturer names and facility identifiers on labels with possible electronic options. - Manufacturers and API suppliers would have to list each supplier of active pharmaceutical ingredients, intermediates, and in-process materials and report how much of the drug used materials from each supplier. New reporting elements set by the Secretary would become required no earlier than 6 months after final rules. - Labels would need to show the original manufacturer of each active pharmaceutical ingredient, each manufacturer if different, and the packer or distributor, plus unique facility identifiers. The Secretary could allow reasonable variations or alternative placement including electronic labeling. - Clinicians, pharmacies, and regulators would get clearer origin and supplier information on reports and labels to help trace ingredient sources and review certificates of analysis.

## Cosponsors (3)

- Rep. Crenshaw, Dan [R-TX-2] (R-TX), 2026-04-16T00:00:00.000Z
- Rep. Schrier, Kim [D-WA-8] (D-WA), 2026-04-16T00:00:00.000Z
- Rep. Hinson, Ashley [R-IA-2] (R-IA), 2026-04-16T00:00:00.000Z

## Provisions PRIA read

- Drug origin labels for manufacturers: mixed, medium. If enacted, the bill would require drug labels to show the name and place of business and a unique facility identifier for the original manufacturer of a drug or each active pharmaceutical ingredient (API). For APIs, the original manufacturer's name, place of business, and facility identifier could…
- New drug supply reporting rules: mixed, medium. If enacted, this bill would require companies that file drug manufacturing reports to identify the supplier of every active pharmaceutical ingredient (API), API intermediate, and in-process material used to make a drug. Reports would also show how much of a drug was made using materials from each s…

## Related bills

- 119-hr-6900: American Affordability Act of 2025
- 119-hr-7977: Energy Bills Relief Act
- 119-hr-3151: SHIPS for America Act of 2025
- 119-hr-1262: Mikaela Naylon Give Kids a Chance Act
- 119-hr-3277: Ensuring Lasting Smiles Act
- 119-hr-1422: Enhanced Iran Sanctions Act of 2025

## Sources
- [119-hr-8339 on Congress.gov](https://www.congress.gov/bill/119th-congress/house-bill/8339)

## Related
- [119-hr-6900: American Affordability Act of 2025](https://policyrisk.com/legislation/119-hr-6900)
- [119-hr-7977: Energy Bills Relief Act](https://policyrisk.com/legislation/119-hr-7977)
- [119-hr-3151: SHIPS for America Act of 2025](https://policyrisk.com/legislation/119-hr-3151)
- [119-hr-1262: Mikaela Naylon Give Kids a Chance Act](https://policyrisk.com/legislation/119-hr-1262)
- [119-hr-3277: Ensuring Lasting Smiles Act](https://policyrisk.com/legislation/119-hr-3277)
- [119-hr-1422: Enhanced Iran Sanctions Act of 2025](https://policyrisk.com/legislation/119-hr-1422)
- [All bills in Congress](https://policyrisk.com/legislation)

Source: PRIA, https://policyrisk.com/legislation/119-hr-8339 (as of 2026-11-01).